<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Acorda Therapeutics Inc. | Company News & Executive Profiles - ACOR | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/acorda+therapeutics+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Acorda Therapeutics Inc.]]></description>
	<s:counts start="0" returned="10" found="20" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Positive FDA Panel Outcome for Acorda Therapeutics]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166617-positive-fda-panel-outcome-for-acorda-therapeutics%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: On 4/23/09, Acorda Therapeutics ACOR announced the resubmission of its NDA for Fampridine-SR Amaya to the FDA as a new therapy being developed to improve walking ability in people with multiple sclerosis MS in response to a Refuse to File letter for the NDA issued by the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 15 Oct 2009 01:14:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[Stage Set for Acorda Bounce?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F165895-stage-set-for-acorda-bounce%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) have hit a five month low, after documents posted on the U.S. Food and Drug Administration's Website show that some agency investigators have questioned whether Acorda's proposed MS treatment Fampridine-SR should be approved. As subscribers to the BioMedReports FDA Calendar know, a special panel...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Sun, 11 Oct 2009 03:37:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">ACOR,BIIB</category>
	</item>
	<item>
		<title><![CDATA[Bullish on Acorda: New Drug Looks Promising]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F144820-bullish-on-acorda-new-drug-looks-promising%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:  By Jason Napodano, CFA Over the past few months, we have become increasingly confident Acorda Pharmaceuticals' ACOR application for Fampridine-SR looks strong -- from a clinical data standpoint. The application contains data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two phase...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 23 Jun 2009 05:04:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[Acorda Pops on Good News]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F136053-acorda-pops-on-good-news%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   By Jason Napodano, CFA We upgraded shares of Acorda Therapeutics, Inc. ACOR the day after the FDA issued the RTF ("refuse to file") letter on April 1, 2009. At that time the shares were hit hard -- down to the $18 level -- and we noted...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 07 May 2009 02:41:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[FDA Calendar Updates: Acorda, Roche]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F135962-fda-calendar-updates-acorda-roche%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 06 May 2009 11:45:01 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[Why I Doubt the FDA Will Approve Acorda's Fampridine]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F132889-why-i-doubt-the-fda-will-approve-acorda-s-fampridine%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Dr. Anthony submits: Yesterday there was an announcement that Acorda (NASDAQ: ACOR) has amended their NDA application for fampridine. After after taking a closer look at their Phase III study (MS-F203), here is a reason why come February 23, 2010 the FDA will provide a verdict of NOT APPROVED or...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 24 Apr 2009 12:52:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/dr.+anthony.html"><![CDATA[Dr. Anthony]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[Acorda Down on FDA Delay]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F128755-acorda-down-on-fda-delay%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   This morning, Acorda Therapeutics ACOR received a &#8220;refuse to file&#8221; (RTF) letter from the U.S. FDA regarding its new drug application (NDA) for Fampridine-SR, the company&#8217;s novel therapy designed to improve walking ability in people with multiple sclerosis.  According to management on the conference call...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 31 Mar 2009 11:55:30 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[Behind the Acorda Rumors]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F122924-behind-the-acorda-rumors%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Bill Luby submits:  Rumors are a part of Wall Street. They always have been and they always will be.   For the most part I tend to ignore the rumors and not bother to mention them on the blog, but occasionally one is too interesting to pass up...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 26 Feb 2009 11:42:41 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/bill+luby.html"><![CDATA[Bill Luby]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">ACOR,BIIB</category>
	</item>
	<item>
		<title><![CDATA[Acorda Therapeutics Inc. Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-272344.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Thank you. Operator Instructions And your first question comes from the line of Joel Sendek from Lazard Capital Markets. Joel Sendek - Lazard Capital Markets Hi, thanks. So I have a question about the partnering in. Obviously it&#8217;s understandable that you don&#8217;t want to be...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 24 Feb 2009 07:44:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[Acorda Therapeutics, Inc., Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-246354.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator Instructions.  Our first question will come from the line of Matt Roden with J.P. Morgan. Matt Roden - J.P. Morgan  I have a couple of questions on the European regulatory discussions.  First, just to clarify, should we assume that no additional clinical...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 04 Nov 2008 10:12:08 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/decision.html"><![CDATA[Decision]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/decision.html"><![CDATA[Decision]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
</channel>
</rss>
